HASBROUCK HEIGHTS, N.J.--(BUSINESS WIRE)--Jan. 10, 2006--Nymox Pharmaceutical Corporation (NASDAQ:NYMX) today provided an update on the progress of its ongoing multi-center Phase 2 trial of NX-1207, the Company’s novel drug treatment for benign prostatic hyperplasia (BPH). The trial is occurring at 35 U.S. sites and is nearing completion. An independent Data Monitoring Committee (DMC) will shortly make its recommendations to the Company, based on efficacy and safety data from the trial. Nymox expects to report on the independent DMC recommendations in the near future. The Company has previously provided internal safety review updates which have shown that there have been no significant safety issues thus far with NX-1207 in the trial.
